Gastric cancer is the second most common cause of cancer related
deaths after Lung cancer (10.4% of all cancer related deaths). 60% cases occur in the developing world
linked to dietary habits and unhealthy food preservation practices. By using
immunotherapy and immune oncology, researchers are getting success in treating
gastric cancer.
 |
| www.gapsos.com |
In the
United States, about 22,220 cases were diagnosed (13,730 in men and 8,490 in
women). Additionally, in the same year about 10,990 death cases (6,720 men and
4,270 women) are estimated at 2014. Gastric cancer
accounts for 989600 new cases and 738000 deaths annually across the world.H.
Pylori bacteria infection of the stomach is most common risk for this cancer.
The people affected with this cancer having history of stomach
surgery; face a greater risk due to alteration in the normal pH of the stomach.
Stomach Disorders include Pernicious anaemia, achlorhydria and atrophic
gastritis 6 times more prone. Smoking hereditary and genetic factors are poorly
understood (KRAS mutation, c-met amplification) rarely, some gastric ulcers may
turn into cancer.
Types 90% arise from the glandular cells of the stomach wall and
are called adenocarcinoma. Others are Gastric Lymphomas (cancer of gastric
lymphatic tissue) Soft tissue sarcomas (Leiomyosarcomas) Carcinoids.
Non-specific symptoms in primary stage likenausea, fever,
vomiting,indigestion and sometimes pain, bloated feeling after eating, loss of
appetite, dark colored stools (due to the presence of blood) and a feeling of
tiredness (due to anaemia). Late symptoms include jaundice, peritoneal and
pleural effusions. Usually, Hepatomegaly occurs in presence of an enlarged left
supraclavicular lymphnode (Virchow's sign) is a typical finding.
The treatment protocols to
stimulate immunity against Gastric cancer are done by using various
immunotherapeutic agents like monoclonal antibodies (MABs), a vaccine based
immunotherapy and adoptive cell therapy.
Many MABs
and vaccines are under clinical trials for Food and Drug Administration (FDA)
approval. Generally, a vaccine based immune Oncology; act as enhancing the
potential of the patient’s immune system to expands tumour specific T cells as
effectors T cells.
Global Allied Pharmaceuticals (GAP) has new
technology to treat cancers on the basis of immune oncology and immunotherapy.
GAP has new approaches to find out the disease condition. Our experts provide
suitable therapy to patient on the basis of cancer stage.
For more information
kindly visit us at www.gapsos.com
No comments:
Post a Comment